Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

PFE stock​ today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...

Pfizer (PFE) reported $17.56 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per ...